UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Biohaven Pharmaceuticals is implementing good security practices.
Rimegepant (BHV-3000; formerly BMS-927711) is an investigational drug candidate for the treatment of migraine. Originally discovered at Bristol-Myers Squibb, it is currently under development by Biohaven Pharmaceuticals.
This report shows a preliminary security rating for Biohaven Pharmaceuticals. UpGuard scans billions of digital assets daily, in depth, across thousands of vectors. Data leak detection, vulnerability scanning and identity breach detection are just some of the advanced capabilities offered by the UpGuard platform.Get a deeper scan →
Read more about the latest issues in cybersecurity
A man-in-the-middle attack (MITM attack) is a cyber attack where an attacker relays and possibly ...
Domain hijacking is the act of changing the registration of a domain name without the permission of ...
Compare Biohaven Pharmaceuticals's security performance with other companies